PDCD1 and nonpapillary renal cell carcinoma: Recently, the technique of using PD-1/PD-L1 monoclonal antibodies combined with vascular targeted therapy has attracted the attention of many researchers, and it has been demonstrated to be effective in prolonging OS in patients with ccRCC [9].